Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of PCN (Pregnenolone-16a-carbonitrile) to preparation of medicine for treating related diseases of chronic kidney diseases

A technology for chronic kidney disease and related diseases, applied in the new application field of PCN, which can solve the problems of no research reports and no PCN yet

Inactive Publication Date: 2018-07-24
NANJING CHILDRENS HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no research report on CKD
At present, there is no report that PCN can fight against CKD-related diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PCN (Pregnenolone-16a-carbonitrile) to preparation of medicine for treating related diseases of chronic kidney diseases
  • Application of PCN (Pregnenolone-16a-carbonitrile) to preparation of medicine for treating related diseases of chronic kidney diseases
  • Application of PCN (Pregnenolone-16a-carbonitrile) to preparation of medicine for treating related diseases of chronic kidney diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Effect of PCN on UUO-induced CKD renal pathology.

[0028] Male C57BL / 6 mice weighing 18-22 g were taken and divided into 3 groups, namely the control group, the UUO model group and the PCN treatment group (n=8).

[0029] Control group: intraperitoneal injection of equal volume medium once a day for 8 days in total;

[0030] UUO model group: unilateral ureteral ligation;

[0031] PCN treatment group: PCN was administered for 2 days in advance (intraperitoneal injection, 100 mg / kg PCN, 200 μL / time), once a day, followed by unilateral ureteral ligation, followed by PCN treatment for 6 days after operation, and 6 days after unilateral ureteral ligation, they were executed Mice, blood and kidney tissue were collected.

[0032] The kidney samples of each group were made into wax blocks, sectioned and subjected to Masson staining to detect the degree of tubulointerstitial fibrosis. The experimental results are shown in figure 1 a. It can be seen from the results...

Embodiment 2

[0034] Example 2 The effect of PCN on the expression of molecules related to tubulointerstitial fibrosis induced by UUO.

[0035] The effect of PCN on the expression of UUO-induced tubulointerstitial fibrosis-related molecules was studied by QPCR and Western blot.

[0036] Such as figure 2 As shown in A, the effect of PCN on the expression of molecules related to tubulointerstitial fibrosis induced by UUO was studied by QPCR method. In the UUO-induced CKD model, the expression levels of fibrosis indicators α-SMA, Fibronectin, Collagen I, and Collagen III in the UUO model group were significantly higher than those in the control group, p<0.05. The PCN treatment group can significantly reduce the mRNA levels of α-SMA, Fibronectin, Collagen I, and Collagen III, p<0.01.

[0037] Such as figure 2As shown in B, the effect of PCN on the expression of molecules related to tubulointerstitial fibrosis induced by UUO was studied by Western blot. In the UUO-induced CKD model, the fi...

Embodiment 3

[0039] Example 3 Effect of PCN on UUO-induced renal inflammation-related molecules.

[0040] The expression levels of renal inflammation-related molecules were detected by QPCR. The result is as image 3 As shown, the expressions of inflammation-related molecules IL-1β, IL-6, and TNF-α in the UUO model group were significantly increased, p<0.001. The PCN treatment group can significantly reduce the expression levels of IL-1β, IL-6, TNF-α, p<0.05.

[0041] The results showed that PCN could significantly reduce the expression levels of UUO-induced renal inflammation-related molecules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of PCN (Pregnenolone-16a-carbonitrile) to preparation of a medicine for treating related diseases of chronic kidney diseases. The invention discloses a novel indication of the pregnenolone-16a-carbonitrile (PCN). The PCN provided by the invention can be used for alleviating the related diseases of the chronic kidney diseases and the related diseases comprise diseases including renal tubulointerstitial fibrosis degree, expression and secretion of inflammatory factors and the like.

Description

technical field [0001] The present invention relates to a new application of PCN, in particular to the application of PCN in the preparation of medicines for diseases related to chronic kidney disease. Background technique [0002] In recent years, chronic kidney disease (CKD) has become a worldwide public health problem. According to the epidemiological survey results in different regions, the incidence rate is between 8% and 16%. In our country, about 125 million people suffer from CKD. The high incidence of CKD is related to the change of modern people's lifestyle. Diabetes and hypertension have become the main causes of CKD. For decades, although people have extensively explored the pathogenesis and intervention strategies of CKD, so far, there is still a lack of effective means for the prevention and treatment of chronic kidney disease. A considerable number of CKD patients eventually develop end-stage renal disease (ESRD). It requires expensive renal replacement ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P13/12
CPCA61K45/00
Inventor 于晓文张爱华贾占军白咪孟霞许曼
Owner NANJING CHILDRENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com